Drug Identification System

PillID

Home Blog Compare Interactions Search 🌙

How Long Does Kratom Stay in Your System?

Kratom (Mitragyna speciosa) is a plant native to Southeast Asia, related botanically to the coffee family. Its leaves contain dozens of alkaloids — chemical compounds that interact with opioid and adrenergic receptors in the body. It is sold in the United States as a powder, capsule, extract, or tea in health food stores and online retailers, and it occupies an unusual legal and pharmacological space: federally legal but under active regulatory scrutiny, with effects that span stimulant-like properties at lower exposures and opioid-like properties at higher ones.

Understanding how long kratom remains in the system matters for drug testing awareness, understanding drug interactions, and recognizing physical dependence. The research base on kratom pharmacokinetics is substantially thinner than for FDA-approved medications, but the available data provides reasonable estimates.

Detection Windows by Test Type

Test Type	Detection Window	Notes
Urine (standard panel)	Not detected	5- and 10-panel tests do not screen for kratom alkaloids
Urine (kratom-specific)	Up to 9 days	Specialized immunoassay required; detection window longer in heavy users
Blood	Up to 2 days	Mitragynine detectable up to ~48 hours; less commonly tested
Hair	Theoretically detectable	No validated commercial hair test exists; research only

Kratom's Active Alkaloids

The two primary pharmacologically active alkaloids in kratom are:

• Mitragynine: The most abundant alkaloid, comprising approximately 66% of total alkaloid content in dried kratom leaf. It acts as a partial opioid agonist and also interacts with adrenergic and serotonergic receptors. Its elimination half-life is approximately 9 hours in available human studies. Using the 5 half-life estimation, full elimination takes roughly 45 hours — under 2 days — for mitragynine itself.
• 7-Hydroxymitragynine: Present in much smaller quantities but substantially more potent at opioid receptors. It is also a metabolite of mitragynine, formed during liver metabolism. Its half-life is approximately 2.5 hours. Despite its shorter half-life, its pharmacological potency makes it clinically significant even at low concentrations.

Beyond these two, kratom contains numerous other alkaloids including speciociliatine, paynantheine, and speciogynine, whose pharmacokinetics are less well characterized. The presence of multiple active compounds, some formed as metabolites of others, means the true elimination picture is more complex than a single half-life number captures.

The extended urine detection window of up to 9 days (in regular heavy users) likely reflects accumulation of alkaloids and metabolites in tissue over time, analogous to how lipophilic drugs distribute into fat stores and clear more slowly in people with chronic high-level use.

Factors That Affect Elimination

• Frequency and duration of use: Casual or occasional users clear kratom alkaloids faster than those with regular, long-term use patterns. Tissue accumulation in chronic users extends effective clearance time significantly beyond what single-dose pharmacokinetics would predict.
• Body fat: Mitragynine has lipophilic properties, meaning it distributes into adipose tissue. Higher body fat percentage is associated with a larger volume of distribution and slower apparent elimination.
• Liver function: Kratom alkaloids are hepatically metabolized. Liver impairment would be expected to prolong elimination, though dedicated studies in hepatically impaired populations are limited.
• CYP enzyme activity: Kratom alkaloids are metabolized by CYP3A4 and CYP2D6 enzymes. Medications or genetic variants that alter these enzymes can affect kratom elimination rate.
• Kidney function: Metabolites are renally excreted; reduced kidney function slows their clearance.
• Product variability: Kratom is not a standardized pharmaceutical product. Alkaloid content varies considerably between strains, vendors, and preparations. The same vendor's "red vein" and "white vein" products may have meaningfully different alkaloid profiles and concentrations.

Regulatory Status

Kratom's legal status in the United States is complicated and actively evolving. At the federal level, the DEA conducted a review process beginning in 2016 that considered emergency scheduling of kratom alkaloids under Schedule I, but withdrew the proposal following significant public comment. As of 2025, kratom remains unscheduled federally — it is not a controlled substance under the Controlled Substances Act.

However, several states have enacted their own bans: Alabama, Arkansas, Indiana, Rhode Island, Vermont, and Wisconsin have state-level prohibitions. Several municipalities within otherwise-permissive states have passed local ordinances. The FDA has issued multiple warnings regarding kratom's safety, and the agency continues to monitor the substance.

The Kratom Consumer Protection Act (KCPA) has been enacted in some states to establish minimum quality and labeling standards for kratom products sold within their borders. The regulatory landscape is fragmented and subject to change.

Drug Interactions

Kratom's pharmacology creates several clinically significant drug interaction risks:

• CYP3A4 and CYP2D6 inhibition: Kratom alkaloids inhibit these two major drug-metabolizing enzymes, potentially raising plasma levels of many co-administered medications. Any drug primarily cleared by CYP3A4 or CYP2D6 — which includes many antidepressants, antipsychotics, opioids, and cardiovascular medications — may accumulate to higher-than-expected levels when combined with kratom.
• Opioids: Additive CNS and respiratory depression. Kratom's partial opioid agonism combined with full opioid agonists can produce unpredictable respiratory effects. Multiple fatalities involving kratom have occurred in the context of concurrent opioid use.
• Benzodiazepines and sedatives: Combined CNS depression; risk of excessive sedation and respiratory compromise.
• Alcohol: Additive CNS depression. The combination is potentially dangerous and is a common finding in adverse kratom events.
• Stimulants: Kratom's stimulant-like effects at lower exposures, combined with amphetamines or cocaine, may produce cardiovascular strain including elevated heart rate and blood pressure.
• Serotonergic medications: Some kratom alkaloids interact with serotonin receptors. Combining kratom with SSRIs, SNRIs, or other serotonergic drugs raises theoretical concern for serotonin syndrome.

Physical Dependence and Withdrawal

Regular kratom use can produce physical dependence, with a withdrawal syndrome that bears resemblance to opioid withdrawal — because the mechanism of dependence involves the same opioid receptor systems. Reported withdrawal symptoms include muscle aches and cramps, insomnia, irritability, nausea, sweating, and anxiety. These symptoms typically begin within 12–24 hours of stopping use and can peak around days 2–3.

Acute physical symptoms generally resolve within 5–7 days for most people, though psychological symptoms including mood disturbances, cravings, and difficulty sleeping can persist longer. People with long-term heavy use may have more prolonged withdrawal timelines.

Frequently Asked Questions

Will kratom show up on a drug test?

Not on a standard test. The 5-panel and 10-panel urine immunoassay screens used by most employers and clinical settings do not include kratom alkaloids. Detecting kratom requires a specialized kratom-specific test ordered explicitly. Without that add-on, kratom use will not be flagged — and it will not produce a false positive on the standard opioid screen.

Is kratom legal?

Federally legal in the US as of 2025, but banned in several states (Alabama, Arkansas, Indiana, Rhode Island, Vermont, Wisconsin) and some municipalities within other states. The regulatory landscape is actively evolving; verifying current law in your specific state and locality is advisable. The FDA has issued safety warnings but has not succeeded in restricting kratom nationally as of this writing.

Can kratom cause a positive opioid drug test?

Generally no. Mitragynine and 7-hydroxymitragynine are structurally distinct from the opioids targeted by standard immunoassay panels (morphine, codeine, heroin metabolites). They do not reliably cross-react with standard opioid screens. Some isolated case reports describe unexpected cross-reactivity on certain immunoassay platforms, but confirmatory GC-MS or LC-MS/MS testing clearly differentiates kratom alkaloids from controlled opioids.

How long does kratom withdrawal last?

For most regular users, acute physical withdrawal symptoms begin within 12–24 hours of the last use and peak around days 2–3. Significant improvement in physical symptoms typically occurs within 5–7 days. Psychological symptoms — mood changes, anxiety, difficulty sleeping, and cravings — can persist for several additional weeks in people with long-term heavy use patterns. The overall timeline is broadly comparable to opioid withdrawal, though often described as milder in intensity.